Proteon Therapeutics Inc (PRTO) Given Consensus Rating of “Hold” by Brokerages
Shares of Proteon Therapeutics Inc (NASDAQ:PRTO) have earned an average recommendation of “Hold” from the six brokerages that are currently covering the company, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $3.00.
PRTO has been the topic of a number of recent analyst reports. Zacks Investment Research raised Proteon Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 13th. Robert W. Baird set a $3.00 price target on Proteon Therapeutics and gave the stock a “hold” rating in a research report on Wednesday, March 14th. HC Wainwright set a $2.00 price target on Proteon Therapeutics and gave the stock a “hold” rating in a research report on Friday, March 16th. ValuEngine raised Proteon Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 2nd. Finally, Cowen reissued a “hold” rating on shares of Proteon Therapeutics in a research report on Thursday, May 10th.
Shares of NASDAQ:PRTO traded up $0.10 during midday trading on Thursday, reaching $2.25. The company had a trading volume of 22,442 shares, compared to its average volume of 45,291. The company has a market cap of $38.88 million, a P/E ratio of -1.06 and a beta of 1.52. Proteon Therapeutics has a 1-year low of $1.20 and a 1-year high of $2.85.
A hedge fund recently raised its stake in Proteon Therapeutics stock. Renaissance Technologies LLC boosted its holdings in shares of Proteon Therapeutics Inc (NASDAQ:PRTO) by 17.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 201,500 shares of the biopharmaceutical company’s stock after buying an additional 29,600 shares during the quarter. Renaissance Technologies LLC owned approximately 1.14% of Proteon Therapeutics worth $383,000 at the end of the most recent reporting period. 50.60% of the stock is currently owned by hedge funds and other institutional investors.
About Proteon Therapeutics
Proteon Therapeutics, Inc, a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to improve hemodialysis vascular access outcomes.
Receive News & Ratings for Proteon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.